OpenAI Announces New Guaranteed Capacity Offering to Address Customer Compute Demand Tepid Demand at US Treasury Auction Reflects Geopolitical Concerns Over Iran CIBC CM Crushes Q1 2026 Estimates EPS 276 Tops Views SpaceX IPO Plans Signal Massive Investment in Rockets and AI Chinas Robotics Push Poses Competitive Challenge for Global Players Musk Says Smaller Bitcoin Treasuries Increase Holdings by 603 BTC Amid Pause in Major Accumulation Strategy India Diversifies Crude Oil Sourcing with Increased Reliance on Russia Brazil and Venezuela Diamondback Energy Rides Oil Price Surge as Geopolitical Unrest Drives Sector Volatility Oil and LNG Tankers Depart Strait of Hormuz Bound for Pakistan and China Nvidia Stock Approaches Key Level as Market Watchers Eye Potential Breakout Commercecom Inc Series 1 CMRC Q1 2026 Earnings EPS Surges Past Estimates Amid Undisclosed Revenue CBFV Q1 2026 Earnings EPS Beats Estimates by 181 as Stock Remains Unchanged CSR Q1 2026 Earnings Widely Misses EPS Estimates Stock Declines CARE Q1 2026 Earnings EPS Falls 857 Below Consensus Shares Slip BRBS Q1 2026 Earnings Positive EPS Surprise Amid Market Headwinds Lucid Diagnostics Inc Q1 2026 Earnings WiderThanExpected Loss as PreRevenue Diagnostics Firm Advances Product Commercialization Aytu BioPharma Gains 164 as Stock Tests Key Resistance at 228 Petrobras PBR Slips 269 as Oil Sector Headwinds Pressure Shares Expro Group Holdings XPRO Declines 179 Approaching Critical Support at 1407 Gain Therapeutics GANX Bounces Back Testing Key Resistance at 187 Flowserve FLS Gains 128 as Technical Levels Point to Potential Upside Post Office Horizon Scandal Inquiry Faces Critical Funding Crisis FiveYear Delay Looms JILL Q1 2026 Earnings EPS Beats Estimates Despite Loss Stock Rises DuPont DD Plunges 39 as Key Support Level Approaches What Investors Should Know Dollar Tree Inc DLTR Fiscal 2027 Q1 Earnings Preview Resilient Value Play Poised for Margin Upside Is Amneal AMRX stock testing support Amneal posts 557 pct EPS beat vs street estimates TCRT Alaunos Therapeutics posts wider Q4 2023 loss than analyst estimates with shares slipping 039 percent in todays trading Merck Co MRK Upgraded 2026 Guidance and HIV Drug Approval Reinforce But Do Not Reshape LongTerm Investment Thesis What would it take for Canterbury CPHC to double from here Buying Pressure 20260508 What Grupo OMAB segment performance reveals Grupo posts 121 EPS miss vs Street estimates TAL TAL Stock Future Potential Review 1852 EPS beat trounces analyst earnings estimates